General characteristics | |
---|---|
Age, years | 55 (21–71) |
Female, n (%) | 16 (84) |
BMI, kg/m2 | 25 (21–37) |
Current smoker, n (%) | 5 (26) |
Creatinin, µmol/L | 74 (52–98) |
eGFR, ml/min/1.73 m2 | 86 (66–152) |
Haemoglobin, mmol/L | 8.2 (6.4–9.5) |
Erythrocyte folate, nmol/L | 1630 (728–2283) |
Characteristics of Crohn’s disease | |
---|---|
Age at diagnosis, n (%) ≤ 16 years 17–40 years > 40 years | 4 (21) 7 (37) 8 (42) |
Location of disease, n (%) ileum colon ileum and colon | 2 (11) 4 (21) 13 (68) |
Disease behaviour, n (%) inflammatory structuring penetrating | 11 (58) 5 (26) 3 (16) |
Peri-anal disease, n (%) | 6 (32) |
Duration of disease, years | 15 (2–54) |
Disease activity | |
---|---|
Flare following PGA, n (%) | 4 (21) |
CRP, mg/L | 2.2 (0.9–20) |
Medication | |
---|---|
Subcutaneous use, n (%) | 12 (63) |
Duration of MTX use, months | 77 (7–202) |
Co-therapy with TNF-α inhibitor, n (%) | 7 (37) |
MTX dose, mg/week, n (%) 15 10; 20; 25 | 16 (84) 1 (5); 1 (5); 1 (5) |
Folic acid dose, mg/week, n (%) 15 10 5 1.5 | 11 (58) 1 (5) 6 (32) 1 (5) |